Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Journey Medical Corp (DERM)
NASDAQ:DERM
RESEARCH TOOLSreports
Holding DERM?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.2Last Year’s EPS
-$0.59Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -14.13%
|Next Earnings Date:Mar 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted Journey Medical's solid progress with a positive adjusted EBITDA, cost management, and growth potential for DFD-29 despite a year-over-year decline in net product revenue and a reported net loss. The overall sentiment leans towards optimism due to strategic advancements and anticipated market opportunities.Company Guidance
During Journey Medical's Q2 2024 earnings call, the company's executive team provided guidance indicating that they are on track to meet their annual revenue target of $55 million to $60 million, with Q2 net product revenue reaching $14.9 million. The company highlighted the growth of key products, QBREXZA and Accutane, which contributed $12.6 million in revenue for the quarter, with prescriptions increasing by 4,000 and 17,000, respectively, compared to Q2 2023. The executives also emphasized their fourth consecutive quarter of positive non-GAAP adjusted EBITDA, which stood at $300,000, and noted a significant reduction in SG&A expenses by $22 million since 2023. The anticipated launch of DFD-29, a product candidate for rosacea, is expected to further strengthen their market position, with a PDUFA date set for November 4. The company remains focused on achieving its financial guidance and preparing for the potential approval and launch of DFD-29, with the goal of becoming sustainably cash flow positive in the coming quarters and EBITDA positive by 2025.Solid Revenue and Prescription Growth
Journey Medical reported $14.9 million in net product revenue for Q2 2024, demonstrating a solid performance and remaining on track to meet the annual revenue guidance range of $55 million to $60 million. Notably, QBREXZA prescriptions grew by approximately 4,000 and Accutane by 17,000 compared to Q2 2023.
Positive Adjusted EBITDA
The company achieved a positive non-GAAP adjusted EBITDA of $300,000 in Q2 2024, marking the fourth consecutive quarter of positive adjusted EBITDA results.
Cost Management and Reduced Expenses
Since the beginning of 2023, Journey Medical reduced total expenses by approximately $22 million, significantly improving profitability and maintaining a strong cash position.
Clinical Success and Market Potential for DFD-29
DFD-29 for rosacea showed positive Phase III trial results, demonstrating statistical superiority to both placebo and Oracea. The company anticipates market approval later this year, with significant growth potential in the $1.2 billion U.S. rosacea treatment market.
---
DERM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DERM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $5.45 | $5.12 | -6.06% |
| Aug 12, 2024 | $4.22 | $4.82 | +14.22% |
| May 13, 2024 | $3.57 | $3.61 | +1.12% |
| Mar 21, 2024 | $3.82 | $3.30 | -13.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Journey Medical Corp (DERM) report earnings?
Journey Medical Corp (DERM) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is Journey Medical Corp (DERM) earnings time?
Journey Medical Corp (DERM) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DERM EPS forecast?
DERM EPS forecast for the fiscal quarter 2024 (Q4) is -$0.2.
---